dc.contributor.author |
Corda, M. |
|
dc.contributor.author |
Sciurba, J. |
|
dc.contributor.author |
Blaha, J. |
|
dc.contributor.author |
Mahanty, S. |
|
dc.contributor.author |
Paredes, Adriana |
|
dc.contributor.author |
García Lescano, Héctor Hugo |
|
dc.contributor.author |
Nash, T.E. |
|
dc.contributor.author |
Nutman, T.B. |
|
dc.contributor.author |
O'Connell, E.M. |
|
dc.date.accessioned |
2022-08-15T20:11:08Z |
|
dc.date.available |
2022-08-15T20:11:08Z |
|
dc.date.issued |
2022 |
|
dc.identifier.uri |
https://hdl.handle.net/20.500.12866/12021 |
|
dc.description.abstract |
BACKGROUND: Antigen tests for diagnosis and disease monitoring in some types of neurocysticercosis (NCC) are useful but access to testing has been limited by availability of proprietary reagents and/or kits. METHODS/PRINCIPAL FINDINGS: Three previously identified IgM-secreting hybridomas whose IgM products demonstrated specificity to Taenia solium underwent variable heavy and light chain sequencing and isotype conversion to mouse IgG. Screening of these recombinantly expressed IgG anti-Ts hybridomas, identified one (TsG10) with the highest affinity to crude Taenia antigen. TsG10 was then used as a capture antibody in a sandwich antigen detection immunoassay in combination with either a high titer polyclonal anti-Ts antibody or with biotinylated TsG10 (termed TsG10*bt). Using serum, plasma, and CSF samples from patients with active NCC and those from NCC-uninfected patients, ROC curve analyses demonstrated that the TsG10-TsG10-*bt assay achieved a 98% sensitivity and 100% specificity in detecting samples known to be antigen positive and outperformed the polyclonal based assay (sensitivity of 93% with 100% specificity). By comparing levels of Ts antigen (Ag) in paired CSF (n = 10) or plasma/serum (n = 19) samples from well-characterized patients with extra-parenchymal NCC early in infection and at the time of definitive cure, all but 2 (1 from CSF and 1 from plasma) became undetectable. There was a high degree of correlation (r = 0.98) between the Ag levels detected by this new assay and levels found by a commercial assay. Pilot studies indicate that this antigen can be detected in the urine of patients with active NCC. CONCLUSIONS/SIGNIFICANCE: A newly developed recombinant monoclonal antibody-based Ts Ag detection immunoassay is extremely sensitive in the detection of extra-parenchymal NCC and can be used to monitor the success of treatment in the CSF, serum/plasma and urine. The ability to produce recombinant TsG10 at scale should enable use of this antigen detection immunoassay wherever NCC is endemic. |
en_US |
dc.language.iso |
eng |
|
dc.publisher |
Public Library of Science |
|
dc.relation.ispartofseries |
PLoS Neglected Tropical Diseases |
|
dc.rights |
info:eu-repo/semantics/restrictedAccess |
|
dc.rights.uri |
https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es |
|
dc.subject |
Urine |
en_US |
dc.subject |
Enzyme-linked immunoassays |
en_US |
dc.subject |
Cerebrospinal fluid |
en_US |
dc.subject |
Antigen isotypes |
en_US |
dc.subject |
Hybridomas |
en_US |
dc.subject |
Neurocysticercosis |
en_US |
dc.subject |
Blood plasma |
en_US |
dc.subject |
Comparators |
en_US |
dc.title |
A recombinant monoclonal-based Taenia antigen assay that reflects disease activity in extra-parenchymal neurocysticercosis |
en_US |
dc.type |
info:eu-repo/semantics/article |
|
dc.identifier.doi |
https://doi.org/10.1371/journal.pntd.0010442 |
|
dc.relation.issn |
1935-2735 |
|